Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.59 |
| ▸ | XDH | P47989 | 4/20 | 0.58 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.58 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.51 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.46 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191619 | 0.86 | XDH (0.54) | XDHSLC22A12PTGS2PIP4K2APIP4K2B | |
| SCHEMBL27710777 | 0.83 | SOS1 (0.72) | SOS1PTGS2PTGS1CA12CA1 | |
| SCHEMBL4185259 | 0.81 | XDH (0.67) | TDP2XDHSLC22A12SOS1 | |
| SCHEMBL4191826 | 0.81 | TDP2 (0.61) | TDP2XDHSLC22A12SOS1EGFR | |
| SCHEMBL4195767 | 0.81 | PIP4K2A (0.56) | TDP2XDHSLC22A12SOS1PTGS2 | |
| SCHEMBL4194486 | 0.79 | TDP2 (0.70) | TDP2XDHSLC22A12SOS1EGFR | |
| SCHEMBL4152376 | 0.78 | XDH (0.53) | XDHSLC22A12PTGS2PIP4K2APIP4K2B | |
| SCHEMBL4185419 | 0.78 | TDP2 (0.61) | TDP2XDHSLC22A12SOS1EGFR | |
| SCHEMBL4189069 | 0.77 | TDP2 (0.62) | TDP2XDHSLC22A12SOS1EGFR | |
| SCHEMBL8055957 | 0.76 | PTGS2 (0.77) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | TDP2 1940/4885XDH 1630/4885SLC22A12 3973/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | TDP2 1940/4885XDH 1630/4885SLC22A12 3973/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | TDP2 1940/4885XDH 1630/4885SLC22A12 3973/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | TDP2 135/4885XDH 527/4885SLC22A12 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.